The key is how innovative that invention is, whether it meets an unmet need, how unique it is, and whether that research makes sense.
A big part is the quality of the research. The other part, as we were discussing earlier, is about the business environment and whether there is enough stability in the market to be able to work that research in that market and be able to see it through to commercialization.
Our global CEO, the head of global pharma from Switzerland, was here yesterday. He gave a speech to our employee base here in Mississauga. When we asked him what he thought about pharma and what he thought about diagnostics, which is in Laval, he said the number one differentiating factor for the pharmaceutical side that he has noticed in his six months on the job is intellectual property.